Navigation überspringen
Universitätsbibliothek Heidelberg
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Gente, Karolina [VerfasserIn]   i
 Kraus, Franziska V. [VerfasserIn]   i
 Carvalho, Rui A. [VerfasserIn]   i
 Lorenz, Holger [VerfasserIn]   i
 Hoerth, Christian [VerfasserIn]   i
 Günther, Janine [VerfasserIn]   i
 Klika, Karel D. [VerfasserIn]   i
 Graf, Jürgen [VerfasserIn]   i
 Diekmann, Leonore [VerfasserIn]   i
 Schank, Timo Emanuel [VerfasserIn]   i
 Christopoulos, Petros [VerfasserIn]   i
 Hassel, Jessica C. [VerfasserIn]   i
 Lorenz, Hanns-Martin [VerfasserIn]   i
 Souto-Carneiro, Maria Margarida [VerfasserIn]   i
Titel:Distinct immune-effector and metabolic profile of CD8+ T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors
Verf.angabe:Karolina Benesova, Franziska Viktoria Kraus, Rui A. Carvalho, Holger Lorenz, Christian H. Hörth, Janine Günther, Karel D. Klika, Jürgen Graf, Leonore Diekmann, Timo Schank, Petros Christopoulos, Jessica C. Hassel, Hanns-Martin Lorenz, Margarida Souto-Carneiro
E-Jahr:2022
Jahr:3 August 2022
Umfang:12 S.
Fussnoten:Gesehen am 12.06.2023
Titel Quelle:Enthalten in: Annals of the rheumatic diseases
Ort Quelle:London : BMJ Publ. Group, 1939
Jahr Quelle:2022
Band/Heft Quelle:81(2022), 12, Seite 1730-1741
ISSN Quelle:1468-2060
Abstract:Objectives Rheumatic immune-related adverse events (irAE) such as (poly)arthritis in patients undergoing immune checkpoint inhibitor (ICI) treatment pose a major clinical challenge. ICI therapy improves CD8+ T cell (CD8) function, but CD8 contributes to chronic inflammation in autoimmune arthritis (AA). Thus, we investigated whether immune functional and metabolic changes in CD8 explain the development of musculoskeletal irAE in ICI-treated patients. - Methods Peripheral CD8 obtained from ICI-treated patients with and without arthritis irAEs and from AA patients with and without a history of malignancy were stimulated in media containing 13C-labelled glucose with and without tofacitinib or infliximab. Changes in metabolism, immune-mediator release, expression of effector cell-surface molecules and inhibition of tumour cell growth were quantified. - Results CD8 from patients with irAE showed significantly lower frequency and expression of cell-surface molecule characteristic for activation, effector-functions, homing, exhaustion and apoptosis and reduced release of cytotoxic and proinflammatory immune mediators compared with CD8 from ICI patients who did not develop irAE. This was accompanied by a higher glycolytic rate and ATP production. Gene-expression analysis of pre-ICI-treated CD8 revealed several differentially expressed transcripts in patients who later developed arthritis irAEs. In vitro tofacitinib or infliximab treatment did not significantly change the immune-metabolic profile nor the capacity to release cytolytic mediators that inhibit the growth of the human lung cancer cell line H838. - Conclusions Our study shows that CD8 from ICI-treated patients who develop a musculoskeletal irAE has a distinct immune-effector and metabolic profile from those that remain irAE free. This specific irAE profile overlaps with the one observed in CD8 from AA patients and may prove useful for novel therapeutic strategies to manage ICI-induced irAEs.
DOI:doi:10.1136/ard-2022-222451
URL:kostenfrei: Volltext: https://doi.org/10.1136/ard-2022-222451
 kostenfrei: Volltext: https://ard.bmj.com/content/81/12/1730
 DOI: https://doi.org/10.1136/ard-2022-222451
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Arthritis
 Biological Therapy
 Inflammation
 T-Lymphocyte subsets
K10plus-PPN:1848812647
Verknüpfungen:→ Zeitschrift
 
 
Lokale URL UB: Zum Volltext

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69084478   QR-Code

zum Seitenanfang